Long-term acceptance of major histocompatibility complex-mismatched cardiac allograft induced by a low dose of CTLA4IgM plus FK506

Microbiology and Immunology

Volumn 40, Issue 7, 1996, Pages 513-518

  Yamada, Akira ^a,b   Murakami, Masaaki ^a   Ijima, Kenichi ^a   Yagita, Hideo ^c   Okumura, Ko ^c   Komatsu, Sakuzo ^b   Uede, Toshimitsu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Allograft; CTLA4IgG; CTLA4IgM; FK506

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; H2 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; TACROLIMUS;

ALLOTRANSPLANTATION; ANIMAL; ARTICLE; CBA MOUSE; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED LYMPHOCYTE CULTURE; MORTALITY; MOUSE; SURVIVAL;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; H-2 ANTIGENS; HEART TRANSPLANTATION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED CBA; SURVIVAL ANALYSIS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030344862     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.1996.tb01102.x     Document Type: Article

References (27)

1. Arulanandam, A.R.N., Moingeon, P., Concino, M.F., Recny, M.A., Kato, K., Yagita, H., Koyasu, S., and Reinhertz, E.L. 1993. A soluble multimeric recombinant CD2 protein identifies CD48 as a low affinity ligand for human CD2: divergency of CD2 ligands during the evolution of humans and mice. J. Exp. Med. 177: 1439-1450.
2. Baliga, P., Charin, K.D., Qin, L., Woodward, J., Lin, J., Linsley, P.S., and Bromberg, J.S. 1994. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 58: 1082-1090.
3. Bierer, B.E., Peterson, A., Gorga, J.C., Herrmann, S.H., and Burakoff, S.J. 1988. Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor. J. Exp. Med. 168: 1145-1156.
4. Bolling, S.F., Lin, H., Wei, R.-Q., Linsley, P.S., and Turka, L.A. 1994. The effect of combination cyclosporin and CTLA4-Ig therapy on cardiac allograft survival. J. Surg. Res. 57: 60-64.
5. Chahine, A.A., Yu, M., McKernan, M.M., Stoeckert, C., and Lau, H.T. 1995. Immunomodulation of pancreatic islet allografts in mice with CTLA4Ig secreting muscle cells. Transplantation 59: 1313-1318.
6. Fulmer, R.I., Cramer, A.T., Liebelt, R.A., and Liebelt, A.G. 1963. Transplantation of cardiac tissue into mouse ear. Am. J. Anal. 113: 273-285.
7. Harding, F.A., McArthur, J.G., Gross, J.A., Raulet, D.H., and Allison, J.P. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356: 607-609.
8. Jenkins, M.K., and Schwartz, R.H. 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165: 302-319.
9. Larsen, C.P., Ritchie, S.C., Pearson, T.C., Linsley, P.S., and Lowry, R.P. 1992. Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations. J. Exp. Med. 176: 1215-1220.
10. Lenschow, D.J., Zeng, Y., Thistlethwaite, J.R., Montag, A., Brad, W., Bibson, M.G., Linsley, P.S., and Bluestone, J.A. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257: 789-792.
11. Lin, H., Bolling, S.F., Linsley, P.S., Wei, R.-Q., Gordon, D., Thompson, C.B., and Turka, L.A. 1993. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178: 1801-1806.
12. Linsley, P.S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N.K., and Ledbetter, J.A. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173: 721-730.
13. Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L.S., Damle, N.K., and Ledbetter, J.A. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174: 561-569.
14. Linsley, P.S., Wallace, P.M., Johnson, J., Gibson, M.G., Greene, J.L., Ledbetter, J.A., Singh, C., and Tepper, M.A. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257: 792-795.
15. Liu, J. 1993. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol. Today 14: 290-295.
16. Liu, J., Farmer, J.D., Jr., Lane, W.S., Friedman, J., Weissman, I., and Schreiber, S.L. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815.
17. Muller, D.L., Jenkins, M.K., and Schwartz, R.H. 1989. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7: 445-480.
18. Pearson, T.C., Alexander, D.Z., Winn, K.J., Linsley, P.S., Lowry, R.P., and Larsen, C.P. 1994. Transplantation tolerance induced by CTLA4-Ig. Transplantation 57: 1701-1706.
19. Schwartz, R.H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248: 1349-1356.
20. Starzl, T.E., Fung, J., Venkatararaanan, R., Todo, S., Demetris, A.J., and Jain, A. 1989. FK506 for liver, kidney and pancreas transplantation. Lancet ii: 1000-1004.
21. Steurer, W., Nickerson, P.W., Steele, A.W., Steiger, J., Zheng, X.X., and Strom, T.B. 1995. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J. Immunol. 155: 1165-1174.
22. Tan, P., Anasetti, C., Hansen, J.A., Melrose, M., Brunvand, J., Bradshaw, J., Ledbetter, J.A., and Linsley, P.S. 1993. Induction of alloantigen-specinc hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177: 165-173.
23. Traunnecker, A., Schneider, J., Kiefer, H., and Karjalainen, K. 1989. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature 339: 68-70.
24. Thompson, A.W., and Starzl, T.E. 1993. New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol. Rev. 136: 71-98.
25. Turka, L.A., Linsley, P.S., Lin, H., Brady, W., Leiden, J.M., Wei, R.Q., Gibson, M.L., Zheng, X.G., Myrdal, S., Gordon, D., Bailey, T., Bolling, S.F., and Thompson, C.B. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. U.S.A. 89: 11102-11105.
26. Van Seventer, G.A., Shimizu, Y., Horgan, K.J., and Shaw, S. 1990. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J. Immunol. 144: 4579-4586.
27. Yamada, A., and Murakami, M. 1994. Generation of soluble form of CTLA4IgM. Sapporo Med. J. 63: 231-237.